Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated a substantial increase in year-over-year revenue growth, with 4,954 CNS reflecting a 57% increase, aided by a higher mix of new patient starts (NPS) in the pharmacy channel. The company has raised its revenue estimates for 2025 and 2026 to $97.5 million and $136 million respectively, indicating a strong operational performance and a positive outlook for future growth. Additionally, the robust performance in 4Q25, supported by strong new prescription momentum and effective expansion efforts in sales territories, reinforces confidence in Beta Bionics's potential to maintain its premium growth profile with a projected compound annual growth rate (CAGR) of 30-40% through 2028.

Bears say

Beta Bionics Inc faces several fundamental challenges that may negatively impact its stock outlook. First, the company's ability to capture meaningful market share with the iLet Bionic Pancreas is in jeopardy due to competitive pressures and potential difficulties in penetrating the pharmacy channel effectively, which could depress revenue and profitability estimates. Additionally, the need for further capital to support growth initiatives raises concerns about shareholder dilution, compounded by regulatory risks and unfavorable Medicare reimbursement proposals that could hinder market adoption and overall financial performance.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.